Axel Grothey, MD | Authors


Grothey Shares Encouraging Data from Lead-In Phase of BEACON CRC Trial

January 24, 2019

Axel Grothey, MD, discusses the results from the safety lead-in phase of the BEACON CRC trial investigating the triplet regimen of BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and anti-EGFR antibody cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer.